Objective: To investigate the efficacy and safety of matched sibling donor allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the treatment of young patients with multiple myeloma (MM).
Methods: The clinical data of 8 young patients (median age：46 years) with MM who underwent allo-HSCT from HLA-indentical sibling donors in the First Affiliated Hospital of Chongqing Medical University from June 2013 to September 2021 were collected, and their survival and prognosis were retrospectively analyzed.
Results: All the patients were successfully transplanted, and 7 patients could be evaluated the efficacy after transplantation. The median follow-up time was 35.2 (2.5-84.70) months. The complete response (CR) rate was 2/8 before transplantation and 6/7 after transplantation. Acute GVHD developed in 2 cases and extensive chronic GVHD developed in 1 case. Within 100 days, 1 case died of non-recurrent events, and 1-year and 2-year disease-free survival were 6 and 5 cases, respectively. At the end of follow-up, all the 5 patients who survived for more than 2 years survived, and the longest disease-free survival time has reached 84 months.
Conclusion: With the development of new drugs, HLA-matched sibling donor allo-HSCT may be a curable treatment for young patients with MM.
题目: 同胞全相合异基因造血干细胞移植治疗年轻多发性骨髓瘤患者的临床分析.
目的: 探讨同胞全相合异基因造血干细胞移植（allo-HSCT）在治疗年轻多发性骨髓瘤（MM）患者中的疗效及安全性。.
方法: 收集2013年6月至2021年9月于重庆医科大学附属第一医院血液科行同胞全相合allo-HSCT的8例年轻MM患者（中位年龄46岁）的相关资料,并进行生存和预后分析。.
结果: 8例患者均成功植活，移植后7例患者可行疗效评估。中位随访时间为35.2（2.5-84.70）个月。移植前达完全缓解（CR）者为2例，移植后达CR者为6例；2例发生急性GVHD，1例发生广泛型慢性GVHD。100 d内非复发死亡1例，8例患者中1年和2年无病生存分别为6例和5例,截至随访终点，生存超过2年的患者均全部存活，其中1例至今已无病生存84个月。.
结论: 随着新药的逐渐发展，同胞全相合allo-HSCT对年轻MM患者可能是一种可治愈的方法。.
Keywords: allogeneic hematopoietic stem cell transplantation; efficacy; multiple myeloma.